← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Blood coagulation factors
susoctocog alfa
B02BD14
Forms & Strengths
- Lyophilized powder for injection: 500 IU, 1000 IU, 2000 IU, 3000 IU single-dose vials with reconstitution diluent
Adult Dosing
- Congenital hemophilia A with inhibitors: 90 units/kg administered as an intravenous bolus injection every 4 to 12 hours as needed for bleeding episodes
- Acquired hemophilia A: 90 units/kg IV every 4 to 12 hours adjusted based on clinical response and FVIII activity levels
Pediatric Dosing
- Safety and efficacy in pediatric patients (<18 years) with congenital hemophilia A with inhibitors have not been fully established; dosing follows adult weight-based paradigms when clinically indicated
- Acquired hemophilia is exceedingly rare in children; use mirrors adult dosing under specialized pediatric hematology guidance
Indications
- Treatment and control of bleeding episodes in patients with acquired hemophilia A
- Treatment and control of bleeding episodes in patients with congenital hemophilia A with inhibitors
Mechanism of Action
- Recombinant porcine factor VIII (rوروFVIII) functioning as a replacement blood-coagulation factor
- Binds to factor IXa in the presence of calcium and phospholipid to form the tenase complex
- Converts factor X to active factor Xa, leading to thrombin generation and fibrin clot formation
- Specifically designed with low cross-reactivity to human anti-FVIII alloantibodies and autoantibodies
Contraindications
- History of severe hypersensitivity reactions, including anaphylaxis, to susoctocog alfa, hamster protein, or any excipients in the formulation
Adverse Reactions
- Development of inhibitory antibodies directed against porcine factor VIII
- Hypersensitivity reactions including flushing, urticaria, chest tightness, and hypotension
- Thromboembolic events
- Injection site reactions
- Fever
Drug Interactions
- Antifibrinolytic agents (e.g., tranexamic acid, aminocaproic acid): Potential increased risk of thrombosis when used concomitantly; use with caution
- Emicizumab: Concurrent use may increase the risk of thrombotic events or thromboembolism
- Other coagulation factor concentrates: Potential for overlapping thrombogenic effects
Curated Content: Needs Vetting Before Put to Clinical Use